{"id":"NCT00490919","sponsor":"Purdue Pharma LP","briefTitle":"Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain","officialTitle":"Multi-center, Randomized, Double-blind, Placebo-controlled With Open Label run-in Study Assessing Efficacy, Tolerability, Safety of BTDS 10 or 20 Compared to Placebo in Opioid-naïve Subjects With Moderate to Severe, Chronic Low Back Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2008-07","completion":"2008-10","firstPosted":"2007-06-25","resultsPosted":"2010-09-09","lastUpdate":"2012-09-10"},"enrollment":539,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Low Back Pain"],"interventions":[{"type":"DRUG","name":"Buprenorphine transdermal system","otherNames":["Butrans™"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Double-blind BTDS 10 or 20","type":"EXPERIMENTAL"},{"label":"Double-blind Placebo TDS","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to determine the analgesic efficacy and safety of Buprenorphine Transdermal System (BTDS) 10 and 20 compared to placebo in opioid-naïve subjects with moderate to severe chronic low back pain. The double-blind treatment intervention duration is 12 weeks, during which time supplemental analgesic medication (immediate-release oxycodone for the first 6 days post-randomization and acetaminophen or ibuprofen for the remainder of the double-blind phase) will be provided to all subjects in addition to study drug.","primaryOutcome":{"measure":"Average Pain Over the Last 24 Hours Scores at Week 12 of the Double-blind Phase.","timeFrame":"Prerandomization phase consisted of a 6-10 day screening period and a <27 day open-label run-in period; and a 12-week double-blind phase.","effectByArm":[{"arm":"Double-blind BTDS","deltaMin":7.24,"sd":1.263},{"arm":"Double-blind Placebo TDS","deltaMin":7.17,"sd":1.223}],"pValues":[{"comp":"OG000 vs OG001","p":".0104"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":86,"countries":["United States"]},"refs":{"pmids":["21945130"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":256},"commonTop":["Nausea","Headache","Application site pruritus","Dizziness","Somnolence"]}}